Pharmacogenomics: a clinician's primer on emerging technologies for improved patient care.
暂无分享,去创建一个
R. Kisabeth | J M Rusnak | R M Kisabeth | D P Herbert | D M McNeil | J. Rusnak | J. Rusnak | D. McNeil | D. P. Herbert | David P. Herbert | Dennis M. McNeil
[1] C. P. Nogueira,et al. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[2] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[3] E. Vesell,et al. Genetic control of dicumarol levels in man. , 1968, The Journal of clinical investigation.
[4] J. Gummert,et al. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient , 1993, The Lancet.
[5] Kyoichi Ohashi,et al. Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer , 1998, Annals of Internal Medicine.
[6] J. Turgeon,et al. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. , 1999, Pharmacogenetics.
[7] Detection. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .
[8] R. Diasio,et al. Clinical implications of dihydropyrimidine dehydrogenase inhibition. , 1999, Oncology.
[9] P. Beaune,et al. Human cytochromes P450 , 1999 .
[10] E. Smeraldi,et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine , 1998, Molecular Psychiatry.
[11] M. Relling,et al. Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.
[12] P. K. Lunde,et al. Disease and Acetylation Polymorphism , 1977, Clinical pharmacokinetics.
[13] J. Turgeon,et al. Involvement of CYP2D6 activity in the N-oxidation of procainamide in man. , 1999, Pharmacogenetics (London).
[14] W. Kalow,et al. A METHOD FOR THE DETECTION OF ATYPICAL FORMS OF HUMAN SERUM CHOLINESTERASE. DETERMINATION OF DIBUCAINE NUMBERS , 1957 .
[15] G. Discombe. Letter: Medical nemesis. , 1974, Lancet.
[16] W. Kalow,et al. The relation between dose of succinylcholine and duration of apnea in man. , 1957, The Journal of pharmacology and experimental therapeutics.
[17] Steven E. Bayer,et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.
[18] E. Vesell,et al. Genetic Control of Drug Levels in Man: Phenylbutazone , 1968, Science.
[19] S. Shak. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. , 1999, Seminars in oncology.
[20] D. Thomason,et al. Impact of genetic polymorphisms of the β2‐adrenergic receptor on albuterol bronchodilator pharmacodynamics , 1999, Clinical pharmacology and therapeutics.
[21] G. Aithal,et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.
[22] B. Vogelstein,et al. p53 mutations in human cancers. , 1991, Science.
[23] S. Green,et al. Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. , 1995, The Journal of clinical investigation.
[24] F. Collins,et al. Shattuck lecture--medical and societal consequences of the Human Genome Project. , 1999, The New England journal of medicine.
[25] P. Corey,et al. Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .
[26] Brian Lipworth,et al. Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics , 1997, The Lancet.
[27] D. Bentley,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.
[28] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[29] U. Meyer,et al. Molecular mechanisms of genetic polymorphisms of drug metabolism. , 1997, Annual review of pharmacology and toxicology.
[30] W. Haseltine. Not quite pharmacogenomics , 1998, Nature Biotechnology.
[31] D. Tinkelman,et al. Take control of high-cost asthma. , 1997, The Journal of asthma : official journal of the Association for the Care of Asthma.
[32] G. Mayer,et al. Angiotensin-Converting Enzyme Gene Polymorphism Determines the Antiproteinuric and Systemic Hemodynamic Effect of Enalapril in Patients with Proteinuric Renal Disease , 1998, Kidney and Blood Pressure Research.
[33] D. Collier,et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine , 1996, Neuroscience Letters.
[34] R. Prough,et al. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. , 1997, Clinical chemistry.
[35] R W Wallace. DNA on a chip: serving up the genome for diagnostics and research. , 1997, Molecular medicine today.
[36] Y. Tanigawara,et al. CYP2C19 genotype–related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori , 1999 .
[37] W. Evans,et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. , 1991, The Journal of pediatrics.
[38] W. Weber,et al. N-acetylation pharmacogenetics. , 1985, Pharmacological reviews.
[39] P. Talmud,et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. , 1998, Diabetes.
[40] R. Weinshilboum,et al. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.
[41] L. Balant,et al. High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data. , 1989, Therapeutic drug monitoring.
[42] R. Branch,et al. Genetically determined drug‐metabolizing activity and desipramine‐associated cardiotoxicity: A case report , 1993, Clinical pharmacology and therapeutics.
[43] S. Sindrup,et al. The pharmacogenetics of codeine hypoalgesia. , 1995, Pharmacogenetics.
[44] P. Jones,et al. The therapeutic response to D-penicillamine in rheumatoid arthritis: influence of glutathione S-transferase polymorphisms. , 1999, Rheumatology.
[45] A. Breckenridge,et al. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study. , 1991, British journal of clinical pharmacology.
[46] P. Seeburg,et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.
[47] M. Ingelman-Sundberg,et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[48] S. Gauthier,et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[49] M. Kasuga,et al. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. , 1999, Journal of gastroenterology.
[50] W. I. Cranston,et al. Clinical observations on the effects of debrisoquine sulphate in patients with high blood-pressure. , 1966, British medical journal.
[51] T. Yamamoto,et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.
[52] E. Vicaut,et al. G894T polymorphism in the endothelial nitric oxide synthase gene is associated with an enhanced vascular responsiveness to phenylephrine. , 1999, Circulation.
[53] I. Hall. Beta 2 adrenoceptor polymorphisms: are they clinically important? , 1996, Thorax.
[54] W. Kalow,et al. On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers. , 1957, Canadian journal of biochemistry and physiology.
[55] P Whelton,et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. , 1995, Hypertension.
[56] O. Lockridge,et al. Complete amino acid sequence of human serum cholinesterase. , 1987, The Journal of biological chemistry.
[57] D. Easton,et al. Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.
[58] A. Breckenridge,et al. In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. , 1990, British journal of clinical pharmacology.
[59] S. Liggett,et al. beta2-adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. , 2000, American heart journal.
[60] R. Poland,et al. The evolving science of pharmacogenetics: clinical and ethnic perspectives. , 1996, Psychopharmacology bulletin.
[61] R. Weinberg,et al. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity , 1986, Molecular and cellular biology.
[62] C. Hudis,et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. , 1999, Seminars in oncology.
[63] F. Cambien,et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study , 1996, BMJ.
[64] J. Connell,et al. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. , 1998, Circulation.
[65] H. Lehmann,et al. The familial incidence of low pseudocholinesterase level. , 1956, Lancet.
[66] C. Watson,et al. DNA chip technolgy , 1999 .
[67] F. Goldwasser,et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[68] K. Ohashi,et al. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans , 1999, Clinical pharmacology and therapeutics.
[69] W. Evans,et al. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient , 1993, The Lancet.
[70] E. Vesell,et al. Genetic Control of Drug Levels in Man: Antipyrine , 1968, Science.
[71] R. Erickson,et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. , 1997, The Journal of clinical investigation.
[72] R. Kim,et al. Alpha1A-adrenergic receptor polymorphism: association with ethnicity but not essential hypertension. , 1999, Pharmacogenetics.
[73] Biochips: an evolving clinical technology. , 1999, Hospital practice.
[74] J. Idle,et al. POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.
[75] R. Weinshilboum,et al. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. , 1992, Pharmacogenetics.
[76] H. Perry,et al. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. , 1970, The Journal of laboratory and clinical medicine.
[77] K. Ohashi,et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans , 1999 .
[78] M. Ingelman-Sundberg,et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine , 1993, The Lancet.
[79] A. Di Rienzo,et al. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. , 1999, Pharmacogenetics.
[80] U. Brinkmann,et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.